Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01712087
Other study ID # NM-PMK-1001
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date October 1, 2012
Est. completion date December 17, 2017

Study information

Verified date January 2019
Source Codman & Shurtleff
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This post-approval study will primarily evaluate the long-term safety of the MedStream Programmable Infusion System when used in combination with Baclofen for the treatment of severe spasticity. A secondary objective, to assess long-term effectiveness, based on the observed scores on the Ashworth Scale (rigidity for the lower extremities) and their Spasm Scores over the 36-month follow-up period will also be described.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date December 17, 2017
Est. primary completion date December 17, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- The subject is a viable candidate for "de novo" or continued (pump replacement) therapy for the treatment of severe spasticity with intrathecal Baclofen delivered by an implantable programmable pump.

- The subject or his/her Legally Authorized Representative must voluntarily provide Informed Consent for participation in this study in accordance with 21 Code of Federal Regulations (CFR) Part 50.

- The subject is willing to comply with the protocol-specified follow-up visit requirements for a period of 36 months after implant.

- The subject has an anticipated life expectancy of 24 months or greater.

- The subject must be 18 years of age or older at time of MedStream implant procedure.

- The subject is of sufficient body size to accommodate pump placement, in the opinion of the Investigator.

- The subject will receive a de novo or replacement implant of the MedStream 20 mL or 40 mL pump, MedStream approved catheter(s) and MedStream accessories.

- The Investigator intends to use Baclofen in the pump for treatment of severe spasticity

- The subject is capable of self-reporting spasm frequency.

Exclusion Criteria:

- Concurrent enrollment in an investigational device or drug study that has not completed the required follow-up period.

- Subject has had an infection and/or inflammation at or near the pump and/or catheter implantation site(s) within 30 days preceding enrollment.

- Evidence of a fever or infection within 10 days prior to the surgical implant procedure that, in the opinion of the Investigator might impact a successful pump implant.

- The subject has known hypersensitivity/allergies or contraindication to Baclofen or the materials in the infusion pump or catheter(s).

- The subject has a co-morbid condition that could limit his/her ability to participate in the study or to comply with the follow-up requirements or, which might impact the scientific integrity of the study.

- The subject has a rapid degenerative neurological disease such as lateral sclerosis, amyotrophic lateral sclerosis (ALS), rapidly progressive Multiple Sclerosis, inherited or rapidly progressive leukodystrophies, Moyamoya disease, cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL), thrombophilias, rapidly progressive autoimmune disorders, or any disorder where progression of the underlying spinal cord or a central nervous system (CNS) disease is expected to progress significantly over the next 3 years

- Subject is a prisoner.

- Subject was previously enrolled in this study.

- Subject is pregnant or breastfeeding. (Note: females of child bearing potential must have a negative pregnancy test prior to enrollment in the study).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MedStream Programmable Infusion System
Intrathecal Infusion of Baclofen in the Treatment of Spasticity

Locations

Country Name City State
United States Methodist Hospital Research Institute Houston Texas
United States UMass Memorial Medical Center Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Codman & Shurtleff

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint is the incidence of MedStream system-related Adverse Events (AE) The primary endpoint is the incidence of MedStream system-related AEs (MedStream pump and catheters) based on Clinical Events Committee determination of relationship, that occur from the start of the MedStream implant procedure (incision) until completion of the 24 month follow-up visit 24 Months
Secondary MedStream system-related AEs occurring from 24 to 36 months 36 Months
Secondary Device-related AEs occurring with both MedStream and non-MedStream devices used or implanted during the course of the study. Device-related AEs occurring in subjects with both MedStream and non-MedStream devices used or implanted during the course of the study. Device refers to the pump and intrathecal catheters 24 Months
Secondary Procedure-related AEs Procedure-related AEs including, but not limited to the following study procedures: MedStream system implant, pump refill and bolus, and reprogramming. If non-MedStream devices or components are utilized in these procedures, this will be described. 24 Months
Secondary Drug-related AEs associated with intrathecal Baclofen 24 Months
Secondary Drug-related AEs associated with other intrathecally-administered medications 24 Months
Secondary Disease-related AEs associated with pre-existing conditions Disease-related AEs associated with pre-existing conditions that demonstrate a significant worsening of the disease or an increase in the frequency of episodes since baseline, as determined by the investigator. 24 Months
Secondary Serious Adverse Events (SAEs) 36 Months
Secondary Unanticipated Adverse Device Effects (UADEs) 24 Months
Secondary The secondary effectiveness endpoints will be long-term effectiveness of MedStream System Long-term effectiveness as demonstrated by scores on the Ashworth Scale (lower extremity) and the frequency and severity components of the Penn Spasm Frequency Scale (PSFS) measured pre-implant, post-implant and at each of the protocol-specified study visits. 24 Month
See also
  Status Clinical Trial Phase
Recruiting NCT06150729 - Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
Completed NCT02400619 - Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT Phase 1
Completed NCT01945684 - A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity Phase 3
Completed NCT02261142 - Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal TENS N/A
Completed NCT01444794 - Adult Subjects Suffering From Lower Limb Spasticity Following Stroke
Terminated NCT02877836 - Functional MRI and DTI in the Preoperative Assessment of Dystonia N/A
Completed NCT02334683 - Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia N/A
Completed NCT02170779 - Developing and Testing a Comprehensive MS Spasticity Management Program Phase 2
Recruiting NCT05674604 - Cryoneurolysis for Knee and Shoulder Pain in an Inpatient Setting
Not yet recruiting NCT05926596 - Leg Stretching Using an Exoskeleton on Demand for People With Spasticity N/A
Completed NCT03906305 - Dry Needling and Bobath Treatment Clinical Effects Focused on Stroke Patients N/A
Completed NCT03302741 - Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings Phase 4
Completed NCT02291159 - Effects of DNHS Technique in the Treatment of Upper Limb Spasticity and Function in Stroke N/A
Completed NCT01743651 - Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis Phase 3
Completed NCT01523210 - DTI Study of the Influence of Physiotherapy on Distribution of BoNT in Spastic Muscle N/A
Completed NCT02073513 - Kinesiotaping the Hand in Cerebral Palsy N/A
Completed NCT00607542 - Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity Phase 1/Phase 2
Completed NCT00702468 - Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis Phase 3
Active, not recruiting NCT04815967 - Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2/Phase 3
Completed NCT01457352 - Efficacy and Safety of SPARC0921 in Subjects With Spasticity Phase 3